<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00209638</url>
  </required_header>
  <id_info>
    <org_study_id>HGCSG0002</org_study_id>
    <nct_id>NCT00209638</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer</brief_title>
  <official_title>Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0101</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hokkaido Gastrointestinal Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hokkaido Gastrointestinal Cancer Study Group</source>
  <brief_summary>
    <textblock>
      To assess the usefulness of irinotecan plus S-1 therapy based on the antitumor effect and&#xD;
      survival period. by performing a phase I/II study of this combination in patients with&#xD;
      inoperable or with postoperative gastric cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter Open-label, single-arm, phase I/II clinical trial is conducted on patients with&#xD;
      histological stage IV gastric cancer given irinotecan plus S-1. The usefulness of this&#xD;
      regimens as 1st line therapy for gastric cancer was evaluated by the disease-free survival&#xD;
      rate (DFR), overall survival rate (OS), incidence and severity of adverse event.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <completion_date>April 2003</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective tumor response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response duration, time to progression, overall survival, and safety will also be assessed.</measure>
  </secondary_outcome>
  <enrollment>24</enrollment>
  <condition>Gastric Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        ãƒ» Eligibility criteria&#xD;
&#xD;
          1. Histological diagnosis of gastric adenocarcinoma.&#xD;
&#xD;
          2. Measurable or assessable lesions.&#xD;
&#xD;
          3. Age: 18 ~ 75 years.&#xD;
&#xD;
          4. Performance Status (ECOG): 0 ~ 2.&#xD;
&#xD;
          5. No prior chemotherapy or only one regimen of previous chemotherapy (with a washout&#xD;
             period &gt;4 weeks after the final day of the previous therapy). Adjuvant chemotherapy is&#xD;
             not defined as previous therapy.&#xD;
&#xD;
          6. No history of treatment with CPT-11 or S-1.&#xD;
&#xD;
          7. No history of radiotherapy to the abdomen.&#xD;
&#xD;
          8. Oral intake of S-1 is possible.&#xD;
&#xD;
          9. Adequate function of major organs (bone marrow, heart, lungs, liver etc.). WBC&#xD;
             3,500/mm3 and 12,000/mm3. Hb 10.0 g/dl. Platelet count 100,000/mm3. GOT and GPT&#xD;
             2.5times the upper limit of normal (excluding liver metastasis). T-Bil 2.0mg/dl.&#xD;
             Creatinine &lt;1.5 mg/dl (but if it is 1.0 ~ 1.5 mg/dl, the dose of S-1 can be decreased&#xD;
             according to the dose reduction criteria to allow registration in the trial). Normal&#xD;
             ECG (not considering clinically unimportant arrhythmias and ischemic changes).&#xD;
&#xD;
         10. Predicted survival for &gt;3 months.&#xD;
&#xD;
         11. Able to give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe pleural effusion or ascites.&#xD;
&#xD;
          2. Metastasis to the central nervous system (CNS).&#xD;
&#xD;
          3. Active gastrointestinal bleeding.&#xD;
&#xD;
          4. Active infection.&#xD;
&#xD;
          5. Diarrhea (watery stools).&#xD;
&#xD;
          6. Uncontrolled ischemic heart disease.&#xD;
&#xD;
          7. Serious complications (such as intestinal paralysis, intestinal obstruction,&#xD;
             interstitial pneumonia or pulmonary fibrosis, uncontrolled diabetes mellitus, heart&#xD;
             failure, renal failure, or hepatic failure).&#xD;
&#xD;
          8. Active multiple cancer.&#xD;
&#xD;
          9. Severe mental disorder.&#xD;
&#xD;
         10. Pregnancy, possible pregnancy, or breast-feeding.&#xD;
&#xD;
         11. Flucytosine treatment&#xD;
&#xD;
         12. Gilbert's syndrome.&#xD;
&#xD;
         13. Judged to be ineligible for this protocol by the attending physician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masahiro Asaka, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hokkaido Gastrointestinal Cancer Study Group</affiliation>
  </overall_official>
  <verification_date>April 2006</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>April 19, 2006</last_update_submitted>
  <last_update_submitted_qc>April 19, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2006</last_update_posted>
  <keyword>Irinotecan,</keyword>
  <keyword>S-1,</keyword>
  <keyword>Phase I/II,</keyword>
  <keyword>gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

